Journal: medRxiv

Article Title: Development of a rapid SARS-CoV-2 neutralisation test by detecting antibodies that block interaction of spike protein receptor-binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2)

doi: 10.1101/2021.06.03.21255116

Figure Lengend Snippet: 1a: ACE2 immobilised on Biochip. Anti-SARS-CoV-2 neutralising antibodies block SARS-CoV-2 Spike RBD HRP from binding to ACE2 on Biochip. 1b: SARS-CoV-2 Spike RBD immobilised on Biochip. Anti-SARS-CoV-2 neutralising antibodies block ACE2 HRP from binding to SARS-CoV-2 RBD on Biochip.

Article Snippet: Virus neutralisation antibodies were detected in serum and plasma samples using a blocking chemiluminescent Biochip-based immunoassay on the Evidence Investigator Biochip analyser (SARS-CoV-2 Surrogate Virus Neutralising Assay EV4454, Evidence Investigator analyser EV3602, Randox Laboratories Ltd).

Techniques: Blocking Assay, Binding Assay

Journal: medRxiv

Article Title: Development of a rapid SARS-CoV-2 neutralisation test by detecting antibodies that block interaction of spike protein receptor-binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2)

doi: 10.1101/2021.06.03.21255116

Figure Lengend Snippet: Validation of SARS-CoV-2 Biochip pVNT in a dose response manner. Inhibition of SARS-CoV-2 RBD and ACE2 interaction using specified concentrations of SARS-CoV-2 recombinant neutralising antibodies

Article Snippet: Virus neutralisation antibodies were detected in serum and plasma samples using a blocking chemiluminescent Biochip-based immunoassay on the Evidence Investigator Biochip analyser (SARS-CoV-2 Surrogate Virus Neutralising Assay EV4454, Evidence Investigator analyser EV3602, Randox Laboratories Ltd).

Techniques: Inhibition, Recombinant

Journal: medRxiv

Article Title: Development of a rapid SARS-CoV-2 neutralisation test by detecting antibodies that block interaction of spike protein receptor-binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2)

doi: 10.1101/2021.06.03.21255116

Figure Lengend Snippet: Inhibition of SARS-CoV-2 RBD ACE2 interaction by samples (A-D) collected from patients confirmed neutralising antibody seropositive using the SARS-CoV-2 microneuralisation test. A reduction in % inhibition is observed for all patients using the pVNT as sample dilution increases (starting dilution 1:25). Dotted line indicates SARS-CoV-2 Biochip pVNT cut-off at 50% inhibition.

Article Snippet: Virus neutralisation antibodies were detected in serum and plasma samples using a blocking chemiluminescent Biochip-based immunoassay on the Evidence Investigator Biochip analyser (SARS-CoV-2 Surrogate Virus Neutralising Assay EV4454, Evidence Investigator analyser EV3602, Randox Laboratories Ltd).

Techniques: Inhibition

Journal: medRxiv

Article Title: Development of a rapid SARS-CoV-2 neutralisation test by detecting antibodies that block interaction of spike protein receptor-binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2)

doi: 10.1101/2021.06.03.21255116

Figure Lengend Snippet: Testing of 110 SARS-CoV-2 microneutralisation assay (mVNT) confirmed seropositive or seronegative samples on the SARS-CoV-2 Biochip pVNT. Dotted line indicates SARS-CoV-2 Biochip pVNT cut-off at 50% inhibition.

Article Snippet: Virus neutralisation antibodies were detected in serum and plasma samples using a blocking chemiluminescent Biochip-based immunoassay on the Evidence Investigator Biochip analyser (SARS-CoV-2 Surrogate Virus Neutralising Assay EV4454, Evidence Investigator analyser EV3602, Randox Laboratories Ltd).

Techniques: Inhibition